Click here for slides on this topic


Metformin

An oral antihyperglycemic agent of the biguanide class used to treat type 2 diabetes.
The following content matched the glossary term: Metformin

AACE 2015 guidelines Glycemic Control Algorithm

Top

AACE’s glycemic control algorithm outlines pharmacologic treatment options for diabetes from the 2015 AACE guidelines 

Endocrine Society obesity clinical practice guideline

Top

Summary of guidelines for managing obesity with pharmacologic therapy from the Endocrine Society.

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position

Top

Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014;16:1041-1047.

Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial

Top

Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care. 2014;37(9):2522-2532.

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Metformin Slides Found: 263
Metformin: Indications
Adjunctive Metformin Therapy in Insulin-Treated Patients With Type 2 Diabetes and Suboptimal Glycemic Control
Treating Insulin Resistance Reduces Incidence of Type 2 Diabetes
Risk of Type 2 Diabetes in People With Impaired Glucose Tolerance
Type 2 Diabetes Prevention Studies
US Diabetes Prevention Program Goals Achieved
US DPP Incidence of Type 2 Diabetes With Different Interventions
Diabetes Incidence Rates by Ethnicity With Different Interventions
Effects of Antidiabetic Agents on Weight
DPP: Weight Loss and Activity
Effect of Phentermine on Weight Loss in Obese Patients With Type 1 or Type 2 Diabetes
Effect of Sibutramine on Weight Loss in Obese Patients With Type 2 Diabetes Treated With Metformin
Effect of Sibutramine, Orlistat, and Metformin on Risk Factors for Type 2 Diabetes
Metformin: Indications
Adjunctive Metformin Therapy in Insulin-Treated Patients With Type 2 Diabetes and Suboptimal Glycemic Control
UKPDS Results of Intensive Therapy: Metformin vs Conventional Therapy
Exenatide: Clinical Pharmacology
Exenatide: Effects on Glycemic Control in Combination With Current Oral Therapies
Exenatide: Proportion of Patients Achieving A1C <=7%
Exenatide: Effect on the Beta-Cell
Sustained Reduction in A1C During 1-Yr Treatment With Vildagliptin in Patients With T2D
Change in Body Weight Following 82 Weeks of Exenatide Treatment
Sitagliptin Enhances Glycemic Control, beta-Cell Function in Patients With Type 2 Diabetes Not Controlled With Metformin
ADOPT: Cumulative Incidence of Monotherapy Failure at 5 Years
ADOPT: Adverse Events
ADOPT: Achievement of A1C Levels <7%
Effects of Sitagliptin vs Glipizide on Body Weight in Type 2 Diabetes
Change in A1C for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Sitagliptin + Metformin Improves 24-Hour Glycemic Control
Sitagliptin Improves A1C in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin on 2-Hour Post-Meal Plasma Glucose in Patients With Type 2 Diabetes Not Controlled With Metformin
Changes in A1C Subgroups for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Effects of Sitagliptin vs Glipizide on FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Exenatide + TZD on Blood Glucose in Patients With Type 2 Diabetes
Effect of Exenatide + TZD on Body Weight in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on FPG in Patients with Type 2 Diabetes
RECORD: Study Design
RECORD: Effect of Rosiglitazone or Metformin Add-on to Sulfonylurea on A1C and FPG
RECORD: Effect of Rosiglitazone or Sulfonylurea Add-on to Metformin on A1C and FPG
Effect of Sitagliptin + Metformin on B-Cell Function at 24 Weeks
DPP: Incidence of Type 2 Diabetes
Stroke Risk in Type 2 Diabetes: First 5 Years After Beginning Treatment
Age-Standardized Stroke Rates in Newly Treated Diabetes vs Control
Stroke Risk by Age in Type 2 Diabetes: First 5 Years After Starting Treatment
Effects of Exenatide LAR on A1C in Patients With Type 2 Diabetes
Effects of Exenatide LAR on Weight in Patients With Type 2 Diabetes
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
Effect of Sitagliptin Added to Glimepiride and/or Metformin in Patients With Type 2 Diabetes
Glycemic Control With Addition of Sitagliptin to Glimepiride and/or Metformin
ACCORD: Study Design
ADVANCE: Study Design
ADVANCE Trial: Combined Major Macrovascular and Microvascular Events
ADVANCE Trial: Risk for Major Macrovascular and Microvascular Events
ACCORD Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ACCORD Trial: CV Events With Intensive Blood Glucose Control
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Any Diabetes Endpoint
UKPDS: Intensive Metformin vs Conventional Therapy: Diabetes Endpoints
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive Metformin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Death From Any Cause
UKPDS: Intensive Metformin vs Conventional Therapy: Death From Any Cause
Alogliptin Added to Metformin: A1C
Alogliptin Added to Insulin: A1C
Effect of Sitagliptin vs Rosiglitazone When Added to Metformin Monotherapy
Fasting Levels of Intact GIP and GLP-1 Concentrations and DPP-4 Activity in Patients With Diabetes
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes
Survival Functions for the Secondary Macrovascular Endpoint
Vildagliptin vs Metformin: A1C
Survival Functions for the Primary Macrovascular Endpoint
Improved Glycemic Control When Adding Metformin to Insulin Therapy
RECORD: Study Design
RECORD: CV Death and Hospitalization
RECORD: Time to Primary Endpoint
RECORD: Bone Fracture Rates in Upper and Distal Lower Limbs
RECORD: Conclusion
Liraglutide Vs Sigagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: Design
Liraglutide Vs Sitagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: A1C
CANOE: Low-Dose Combination Therapy With Rosiglitazone Plus Metformin for Diabetes Prevention
CANOE: Development of New-Onset Diabetes With Low-Dose Combination Therapy Vs Placebo
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results Design
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results A1C Reduction
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results
DURATION-4: Design
DURATION-4: Mean Change in A1C from Baseline to Week 26
DURATION-4: Additional Outcomes
DURATION-4: Most Common Adverse Events
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
ACP: Recommendations for Oral Pharmacologic Therapy for Type 2 Diabetes
ACP: Considerations for Oral Pharmacologic Therapy in Type 2 Diabetes
DPP and DPPOS: Timeline
DPP: A Look Back
DPPOS Bridge: Year 4
DPPOS Maintenance: Years 5-10
Long-Term Use of Metformin in DPPOS
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Medication Adherence
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Weight Loss
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Waist Circumference
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase— Achievement of ≥5% Loss of Body Weight
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Achievement of ≥10% Loss of Body Weight
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase— Effect of Adherence on Body Weight, Waist Circumference
Long-Term Use of Metformin in DPPOS: Results Including DPPOS Open-Label Treatment—Metformin Adherence
Long-Term Use of Metformin in DPPOS: Results During DPP—Safety & Tolerability
TODAY Study: Design
TODAY Study: Eligibility Criteria and Run-in Period
TODAY Study: Baseline Characteristics
TODAY Study: Primary Outcome—Loss of Glycemic Control
TINSAL-T2D Trial: Eligibility Criteria and Study Protocol
Long-Term Use of Metformin in DPPOS: Results During DPP—Average Hemoglobin, Hematocrit Levels Over Time
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
DPPOS Substudy: Effect of Regression from Prediabetes to NGR on Diabetes Risk
DPPOS Substudy: NGR Status and Risk Reduction
DPPOS Substudy: NGR Predictors During DPPOS
DPPOS Substudy: Additional Outcomes
EASIE Trial: Design
EASIE Trial: Study and Enrollment Profile
EASIE Trial: Efficacy Population Primary Outcome at Week 24—Change in A1C from Baseline
EASIE Trial: Efficacy Population A1C <7.0% and <6.5% Week 24
EASIE Trial: Safety Population Hypoglycemia and Adverse Events
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Change in A1C from Baseline
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Adverse Events and All-Cause Mortality
EUREXA Trial: Change in Body Weight
EUREXA Trial: Hypoglycemia and Adverse Events
EUREXA Trial: Attainment of A1C <7.0% and ≤6.5%
EUREXA Trial: Primary Outcome—Time to Treatment Failure
EUREXA Trial: Design and Enrollment Profile
EUREXA Trial: Design
CONQUER: Design
BLOOM-DM: Design
BLOOM-DM: Primary and Secondary Endpoints
BLOOM-DM: Subject Profile
SEQUEL: Design Extension of CONQUER Study
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Design
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Change in A1C from Baseline
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Secondary Endpoints
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: CV Safety, Glucose, Adverse Events
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (2 of 3)
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: Design
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: 26-Week Extension Results for A1C Reduction
Liraglutide Treatment for 78 Weeks: Reductions in A1C from Baseline
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Results for Primary Endpoint
Guidelines for Children and Adolescents With Type 2 Diabetes: Insulin Therapy
Guidelines for Children and Adolescents With Type 2 Diabetes: Lifestyle Changes, Metformin for All
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (1 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (2 of 2)
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Background
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Design
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Primary Endpoint
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Mean A1C Change
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: A1C Target at Endpoint
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Mean Body Weight Change
Weight Gain in ACCORD By Type 2 Diabetes Treatment Allocation
Medication Use and Weight Gain in ACCORD
CANTATA-D2: Design
CANTATA-D2: Canagliflozin Noninferior to Sitagliptin for A1C Lowering at 52 Weeks
CANTATA-D2: Significantly Greater FPG Reduction with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Significantly Greater Weight Reduction with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Significant Reductions in Systolic BP with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Effect of Canagliflozin Vs Sitagliptin on Lipid Values at 52 Weeks
CANTATA-D2: Adverse Events at 52 Weeks
Efficacy of Twice-Daily Exenatide Added to Basal Insulin for A1C Reduction: Design
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo : A1C Reduction at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Target A1C Levels at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Body Weight 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Hypoglycemia at 30 Wks
Twice-Daily Exenatide Vs Placebo Added to Basal Insulin: Adverse Events
Metformin: Renal Considerations
ADA Nutrition Guidelines: Priorities for Nutrition Management By Medication
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, Change in A1C at 26 Weeks
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in Patients With Type 2 Diabetes
Liraglutide Reduces A1C Irrespective of Baseline A1C
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Body Weight in
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Fasting Plasma
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on A1
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on Body
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on Fasting
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
US Trends in Type 2 Diabetes Treatment, 1997-2012: Type of Treatment Used, Visit with 2+ Compounds in 2012
US Trends in Type 2 Diabetes Treatment, 1997-2012: Type of Treatment Used, Visit with 1 Compound in 2012
US Trends in Type 2 Diabetes Treatment, 1997-2012: Medication Classes
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
LEAD 6: Study Design
LEAD 6: Change in A1C at 26 Weeks
LEAD 6: Percent at A1C Targets at 26 Weeks
LEAD 6: Change in FPG at 26 Weeks
LEAD 6: Change in Weight at 26 Weeks
IDF 2012 Type 2 Diabetes Guidelines Glucose Treatment Management | NDEI
IDF 2012 Type 2 Diabetes Guidelines Insulin Therapy | NDEI
IDF Type 2 Diabetes Treatment Guidelines Older Adults Elderly | NDEI
Emplagliflozin SGLT 2 A1C EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Weight Loss EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Insulin EMPA-REG MDI Study | NDEI
Empagliflozin SGLT2 Adverse Events EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 EMPA-REG MDI Study | NDEI
Insulin Sulfonlyrea Added to Metformin CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality Design | NDEI
Diabetes Pregnancy Guidelines Noninsulin Therapy | NDEI
Diabetes Pregnancy Guidelines Postpartum Lactation GDM | NDEI
RECORD Rosiglitazone Cardiovascular Effects Slides | NDEI
Sulfonylurea Treatment All-Cause CV Mortality Type 2 Diabetes Treatment | NDEI
Higher CV Risk With Metformin + Sulfonylurea Vs DPP-4 Inhibitor | NDEI
HARMONY 3 Albiglutide A1C Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide FPG Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Weight Loss Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide Type 2 Diabetes Metformin | NDEI
Metformin Sulfonylureas Cancer Risk Type 2 Diabetes | NDEI
Sulfonylureas Metformin Cancer Risk Type 2 Diabetes | NDEI
GLP-1 Receptor Agonists A1C Type 2 Diabetes | NDEI
HARMONY 3 DPP-4 Inhibitors Safety Pancreatitis | NDEI
Cancer Incidence Metformin Sulfonylureas Type 2 Diabetes | NDEI
Reports of Acute Pancreatitis Type 2 Diabetes Drugs | NDEI
Noninsulin Therapies ADA Type 1 Diabetes Guidelines | NDEI Slides
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
ADA EASD Treatment Algorithm Type 2 Diabetes | NDEI
DURATION-3 & LEAD-5 Post-Hoc Analysis Insulin Type 2 Diabetes PPT | NDEI
A1C Reduction GLP-1 RAs & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Similar A1C Goal Achievement GLP-1 RA & Glargine DURATION-3 & LEAD-5 | NDEI
Weight Loss With GLP-1 RA & Increase With Glargine in DURATION-3 & LEAD-5 | NDEI
Hypoglycemia With GLP-1 RA & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Endocrine Society Obesity Guidelines Treating Type 2 Diabetes PPT | NDEI
Canagliflozin & Sitagliptin A1C Type 2 Diabetes ENDO2015 PPT | NDEI
Empagliflozin Vs Linagliptin 2nd-Line Therapy Type 2 Diabetes Obesity ENDO2015 | NDEI
AACE 2015 Guidelines Treating Gestational Diabetes GDM PPT | NDEI
TECOS Sitagliptin Cardiovascular Safety High-Risk Type 2 Diabetes DPP-4 | NDEI
TECOS Cardiovascular Outcomes Sitagliptin DPP-4 | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
TECOS Sitagliptin DPP-4 Inhibitor Pancreatitis Hypoglycemia | NDEI
TECOS Sitagliptin A1C Efficacy DPP-4 Inhibitor CV Safety | NDEI
Diabetes Medications & Weight AHA ADA CVD Prevention Guidelines | NDEI
Sitagliptin Not Associated With Heart Failure in TECOS Type 2 Diabetes | NDEI
AWARD-2: Once-Weekly Dulaglutide Vs Insulin Glargine Type 2 Diabetes | NDEI
Lower A1C With Dulaglutide Vs Insulin Glargine AWARD-2 Results | NDEI
Saxagliptin Not Associated With Fractures in SAVOR-TIMI 53 Analysis | NDEI
Safety of Dulaglutide & Insulin Glargine Pancreatitis AWARD-2 | NDEI
Type 2 Diabetes Prevention ADA Guidelines 2016 | NDEI PPT
Type 2 Diabetes Treatment Algorithm ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
AWARD-2 Design Dulaglutide Vs Insulin Glargine Type 2 Diabetes | PPT
AWARD-2: Lower A1C With Dulaglutide Vs Insulin Glargine Type 2 Diabetes | NDEI
AWARD-2 Similar Adverse Events With Dulaglutide & Insulin Glargine Type 2 Diabetes | NDEI
Metabolic Surgery Postoperative Follow-Up for Type 2 Diabetes Guidelines | NDEI